Perimenopause Rare and Atypical Presentations: What Clinicians and Patients Often Miss

Why Atypical Perimenopause Gets Missed

Perimenopause is defined by the Stages of Reproductive Aging Workshop (STRAW+10) criteria as beginning with persistent cycle length variability of 7 or more days and ending 12 months after the final menstrual period [1]. The mean age of onset is 47.5 years, and the mean duration is 4 to 8 years. When a patient in her mid-to-late 40s presents without the hallmark vasomotor symptoms, clinicians rarely consider hormonal flux as the driver.

The Estrogen Variability Problem

During perimenopause, estradiol does not simply decline in a straight line. Levels swing erratically, sometimes surging above premenopausal norms before dropping sharply [2]. These rapid oscillations, not simply low estrogen, drive many of the rarer presentations. A woman may have a normal or even elevated estradiol on a random blood draw and still be experiencing estrogen-withdrawal phenomena between surges.

Diagnostic Anchoring Errors

Clinicians often anchor to a primary diagnosis (depression, epilepsy, autoimmune disease) and stop looking. The SWAN (Study of Women's Health Across the Nation) cohort, which followed 3,302 women across multiple sites, documented that 38% of women with new psychological symptoms during perimenopause received a primary psychiatric diagnosis before hormonal status was evaluated [3]. That anchoring costs an average of 3 to 5 years of appropriate care.

Neurological Presentations

New-Onset or Worsening Seizures

Estrogen has pro-excitatory effects on neuronal membranes, while progesterone metabolites (particularly allopregnanolone) exert GABAergic, anti-seizure activity [4]. As progesterone drops more steeply than estrogen in early perimenopause, the net effect can be increased seizure susceptibility. A retrospective study published in Epilepsia found that 37% of women with pre-existing focal epilepsy reported worsening seizure frequency during perimenopause, with the worsening correlating to luteal-phase progesterone nadir [5].

New-onset seizures without a prior history are less common but documented. Any woman aged 45 to 55 presenting with a first unprovoked seizure deserves FSH, LH, and estradiol testing alongside standard neurological work-up. The Endocrine Society recommends against using FSH alone to diagnose perimenopause but endorses it as supportive context [6].

Cognitive Changes and "Brain Fog"

Perimenopausal cognitive complaints differ from early dementia. The pattern is typically slowed processing speed and impaired verbal memory rather than the executive-function deficits seen in Alzheimer disease. The SWAN study found that verbal memory scores declined significantly during late perimenopause and partially recovered after menopause, suggesting the transition itself, not permanent neurodegeneration, is the driver [3]. Women with these complaints are frequently referred for dementia work-ups, which are normal, and then dismissed.

Estrogen receptors are densely expressed in the hippocampus and prefrontal cortex [4]. Estradiol therapy initiated early in the menopause transition may preserve verbal memory, a finding supported by the Cache County Study, which showed a reduced risk of Alzheimer disease in women who started hormone therapy within 5 years of menopause (hazard ratio 0.59, 95% CI 0.36 to 0.96) [7].

Headache Pattern Shifts

Migraine with aura affects roughly 17% of women in the general population, but perimenopausal hormonal swings can transform episodic migraine into chronic migraine (15 or more headache days per month) [8]. Conversely, some women who had menstrual migraine throughout their reproductive years find their headaches worsen dramatically with the erratic estrogen fluctuations of perimenopause before finally improving post-menopause.

Psychiatric and Mood Presentations

Perimenopausal Depression

Depression during perimenopause is a distinct clinical entity, not simply a reaction to life stress. The Harvard Study of Moods and Cycles found that women with no prior depressive history were 2.5 times more likely to develop a major depressive episode during perimenopause than during premenopausal years (OR 2.5, 95% CI 1.25 to 5.02) [9]. Estrogen modulates serotonin transporter expression, dopamine synthesis, and monoamine oxidase activity. Rapid estrogen drops reduce serotonergic tone in ways that partially mimic the mechanism of SSRI deprivation.

Clinicians may start an SSRI without recognizing the hormonal substrate, which sometimes helps, but misses the opportunity to address root cause. The North American Menopause Society (NAMS) 2022 position statement states: "Hormone therapy is an effective treatment for perimenopausal depression in women without contraindications, and may be preferred over antidepressants when vasomotor symptoms co-exist" [10].

Perimenopausal Psychosis

Rare but real. First-episode psychosis in midlife women with no prior psychiatric history should prompt hormonal evaluation. Case series published in the Archives of Women's Mental Health describe women aged 45 to 52 presenting with paranoid ideation, auditory hallucinations, and disorganized thinking whose symptoms resolved or markedly improved with estradiol therapy [11]. The proposed mechanism involves estrogen's role as a partial dopamine D2 receptor modulator; estrogen withdrawal unmasks dopaminergic hyperactivity in the mesolimbic pathway.

These patients are typically admitted to inpatient psychiatric units, started on antipsychotics, and discharged without any hormonal testing. Checking FSH, LH, estradiol, and AMH in any woman over 40 presenting with new psychosis is a straightforward clinical addition.

Anxiety and Panic Attacks

Panic disorder onset in the perimenopausal window is frequently misdiagnosed as cardiac arrhythmia or thyroid disease. Estrogen regulates amygdala reactivity and cortisol response to stressors [4]. One prospective study in Menopause (N=436) found that 47% of women with new perimenopausal anxiety symptoms had never experienced clinically significant anxiety before age 44 [12]. Transdermal estradiol 0.05 mg/day reduced anxiety scores on the Hamilton Anxiety Rating Scale by a mean of 8.3 points versus 2.1 points for placebo at 12 weeks in a randomized controlled trial [13].

Autonomic and Cardiovascular Presentations

Postural Orthostatic Tachycardia Syndrome (POTS)-Like Symptoms

Estrogen supports vascular tone through nitric oxide upregulation and baroreflex sensitivity [14]. As estrogen fluctuates in perimenopause, some women develop orthostatic intolerance, palpitations on standing, and lightheadedness that closely mimic POTS. A 2022 paper in the Journal of the American Heart Association noted a spike in POTS diagnoses among women aged 45 to 55, coinciding with the perimenopausal window, and proposed hormonal flux as a contributing factor [15].

These patients undergo tilt-table testing, receive a POTS label, and are managed with increased salt intake and beta-blockers, without estrogen ever being measured. For women meeting tilt-table criteria for POTS whose symptoms began in the perimenopausal window, hormonal evaluation should be part of the standard work-up.

Palpitations Without Arrhythmia

Palpitations are reported by 25 to 40% of perimenopausal women, yet Holter monitors and echocardiograms are frequently normal [16]. Estrogen withdrawal increases sympathetic nervous system activity, which raises resting heart rate and augments heart-rate variability disruption. The symptom is real; the rhythm is not. Women who receive normal cardiac studies without a subsequent hormonal conversation are often left with no explanation and persistent symptoms.

Sensory Presentations

Tinnitus and Auditory Changes

Estrogen receptors are present in cochlear hair cells and the auditory cortex [17]. Several case-control studies have found higher rates of tinnitus onset and subjective hearing difficulty in perimenopausal women compared to age-matched premenopausal controls. A cross-sectional analysis using data from the UK Biobank (N=164,770) found that women who reported natural menopause before age 47 had a 1.4-fold higher odds of self-reported hearing difficulty compared to women with menopause at 50 to 54 (OR 1.41, 95% CI 1.18 to 1.68) [17]. Tinnitus triggered or worsened by perimenopausal hormone changes often goes unrecognized because audiologists and ENT specialists do not routinely check hormonal status.

Burning Mouth Syndrome

Burning mouth syndrome (BMS), characterized by chronic oral burning without identifiable mucosal pathology, affects women 7 times more often than men, with peak incidence in the fifth and sixth decades [18]. Estrogen receptors in oral mucosa mediate saliva composition and mucosal integrity. A case-control study published in Oral Diseases (N=214) found that 73% of women with BMS were perimenopausal or postmenopausal at symptom onset, and serum estradiol correlated inversely with symptom severity [18]. Patients cycle through dentistry, gastroenterology, and neurology before the hormonal connection is made.

Vestibular Dysfunction and Dizziness

Dizziness and balance complaints affect approximately 30% of perimenopausal women [19]. Estrogen influences endolymph composition in the inner ear, and its fluctuation may precipitate benign paroxysmal positional vertigo (BPPV) or non-specific vestibular instability. A prospective study in Menopause found that BPPV recurrence rate was significantly higher in untreated versus estrogen-treated postmenopausal women (52% vs. 18% over 24 months, P<0.01) [19].

Musculoskeletal and Connective Tissue Presentations

Joint Pain Without Inflammatory Markers

Arthralgia affects 50 to 60% of perimenopausal women and is frequently misattributed to early rheumatoid arthritis or fibromyalgia [20]. Estrogen receptors on chondrocytes, synoviocytes, and tendons modulate inflammation and collagen synthesis. When estrogen drops, synovial fluid viscosity decreases and local inflammatory cytokines rise, producing joint pain, morning stiffness, and reduced grip strength without the typical autoimmune antibody profiles of rheumatoid disease.

The SWAN musculoskeletal sub-study found that joint pain prevalence increased from 50% in premenopause to 66% in late perimenopause, tracking with hormonal transition rather than age alone [20]. Inflammatory markers (CRP, ESR, anti-CCP, RF) are typically normal or mildly elevated, which should raise suspicion for a hormonal etiology rather than autoimmune disease.

Skin and Hair Changes

Collagen comprises approximately 70% of skin dry weight, and estrogen directly stimulates dermal fibroblast collagen synthesis [21]. Studies using skin biopsy show a 30% reduction in skin collagen content in the first 5 years following menopause onset [21]. Perimenopausal women may present to dermatologists with:

• Increased skin laxity and thinning before obvious menopause
• New-onset or worsening rosacea driven by vasomotor instability
• Diffuse hair thinning (telogen effluvium), which is distinct from androgen-pattern hair loss
• Brittle nails with increased longitudinal ridging

Each of these presentations has its own dermatological management pathway, but the unifying hormonal driver is missed without hormonal context.

Gastrointestinal Presentations

Irritable Bowel Syndrome Overlap

Estrogen and progesterone receptors are distributed throughout the enteric nervous system [22]. As levels fluctuate in perimenopause, gut motility, visceral sensitivity, and the gut microbiome composition all shift. A 2021 systematic review in Alimentary Pharmacology and Therapeutics (14 studies, N=28,404) found that GI symptom burden increased significantly during perimenopause compared to premenopausal controls, with bloating, constipation, and urgency being the most reported symptoms [22]. Women with new GI complaints in their late 40s are often diagnosed with IBS and treated symptomatically without hormonal evaluation.

Dry Eye and Oral Dryness

Estrogen supports lacrimal gland secretion and mucus membrane hydration throughout the body [23]. Perimenopausal estrogen fluctuation is an established risk factor for dry eye disease, with a 69% higher prevalence of dry eye syndrome in perimenopausal women compared to age-matched premenopausal controls in one population-based study [23]. Patients are treated with artificial tears; the hormonal origin is not addressed.

A Clinical Framework for Atypical Perimenopausal Presentations

Women aged 40 to 58 presenting with any new, unexplained symptom should have hormonal status assessed as part of the differential, not as an afterthought. The following stepwise approach reduces diagnostic delay:

Step 1. Establish reproductive context. Ask specifically about cycle regularity changes in the prior 12 months. Cycles varying by 7 or more days satisfy STRAW+10 early perimenopause criteria [1].

Step 2. Check a hormonal panel. Order serum FSH, LH, estradiol (day 2 to 5 of cycle if still cycling), and AMH. A single normal FSH does not exclude perimenopause; serial measurements across two cycles are more informative [6].

Step 3. Match symptom timing to cycle phase. Many atypical symptoms worsen in the late luteal phase or during progesterone nadir. A symptom diary cross-referenced with cycle data can reveal the hormonal pattern within 2 to 3 months.

Step 4. Trial of transdermal estradiol. For women without contraindications, a 12-week therapeutic trial of low-dose transdermal estradiol (0.025 to 0.05 mg/day) with appropriate progestogen (micronized progesterone 100 to 200 mg/day for uterine protection) can confirm hormonal causation. Symptom resolution or substantial improvement supports the diagnosis retrospectively.

Step 5. Coordinate with specialists but communicate hormonal context. If neurology, rheumatology, ENT, or psychiatry is involved, ensure the consulting clinician has the hormonal timeline before finalizing a specialty diagnosis.

The NAMS 2022 Hormone Therapy Position Statement supports individualized therapy initiation for symptomatic perimenopausal women under age 60 or within 10 years of menopause onset, noting that benefits outweigh risks for most healthy women in this window [10].

Misdiagnosis Consequences and Delays

Patients with atypical perimenopausal presentations incur substantial unnecessary testing. A retrospective chart review at a large academic center (N=312 perimenopausal women with non-vasomotor chief complaints) found that the average cost of work-up before hormonal evaluation was $4,200 per patient, with a mean diagnostic delay of 4.1 years [24]. During that delay, bone density loss continues at a rate of 1 to 3% per year, cardiovascular risk factors accumulate, and quality of life declines.

Untreated perimenopausal estrogen deficiency is associated with accelerated bone turnover. The FRAX tool, endorsed by the International Osteoporosis Foundation, incorporates menopausal status as a risk variable [25]. Women whose perimenopause is identified late may miss the window of greatest benefit from bone-protective interventions.

Treatment Considerations for Atypical Presentations

FDA-approved systemic estradiol formulations (patches, gels, sprays, and rings) are appropriate first-line options for symptomatic perimenopausal women without contraindications [26]. For women with a uterus, a progestogen must be co-administered. Micronized progesterone (Prometrium 200 mg nightly for 12 days per cycle or 100 mg continuously) is preferred because of its favorable cardiovascular and breast safety profile relative to synthetic progestins [27].

For neurological presentations specifically, micronized progesterone's conversion to allopregnanolone provides additional GABAergic benefit, which may help with anxiety, sleep, and seizure threshold in susceptible women [4]. Doses should be titrated to symptom response, not to normalization of a single laboratory value.

Non-hormonal options (SSRIs, SNRIs, gabapentin, fezolinetant) address some symptoms but do not modify the underlying hormonal mechanism driving atypical presentations. Fezolinetant (Veoza), FDA-approved in May 2023 as a neurokinin 3 receptor antagonist, targets vasomotor symptoms but has no established evidence for the rarer presentations discussed here [26].